Please assess the completion status of the following clinical trial:

Trial Title: CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy for AML Patients Not in CR

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed with acute myelogenous leukemia (except acute promyelocytic leukemia) and has failed one or two prior standard induction attempts. Failure is defined as:~* ≥ 30% bone marrow blasts with at least 20% cellularity at mid-cycle bone marrow biopsy or residual AML on subsequent\~ day 28 bone marrow biopsy by morphology, flow, PCR or FISH~* Patients enrolling after only 1 failed induction attempt must meet at least one of the following additional eligibility criteria of high risk: ≥ 60 years of age adverse cytogenetics or molecular characteristics~* AML that progressed out of myelodysplastic syndrome (MDS) is eligible if the patient did not receive treatment directed at the MDS~* HLA-haploidentical related donor (aged 12 to 70 years)~* ≥ 18, but \< 75 years of age~* Karnofsky performance status ≥ 60%~* Adequate organ function within 14 days of study registration (30 days for pulmonary and cardiac) as defined in section 4.5~* Ability to be off prednisone and other immunosuppressive drugs for at least 3 days prior to the NK cell infusion (excluding preparative regimen pre-meds)~* No prior hematopoietic transplant~* Not pregnant or lactating~* Sexually active females of childbearing potential and males with partners of child bearing potential must agree to use birth control~Exclusion Criteria:~* Pregnant or lactating as the treatments used in this study includes drugs that are FDA Pregnancy Category D.~* Acute leukemias of ambiguous lineage~* AML that transformed from previously treated myelodysplastic syndromes~* Prior hematopoietic transplant~* New or progressive pulmonary infiltrates on screening chest x-ray or chest CT scan that has not been cleared by Pulmonary. Infiltrates attributed to infection must be stable/improving (with associated clinical improvement) after 1 week of appropriate therapy (4 weeks for presumed or documented fungal infections)~* Uncontrolled bacterial, fungal, or viral infections including HIV - chronic asymptomatic viral hepatitis is allowed~* Known hypersensitivity to one or more of the study agents used

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Single-arm trial (Type: OTHER): Multi-center, open-label, single-arm, phase I/II clinical trial

Based on this trial design, predict the completion outcome and termination type (if applicable).